Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway

International Journal of Cancer

Volumn 129, Issue 12, 2011, Pages 2916-2927

  Thamilselvan, Vijayalakshmi ^a   Menon, Mani ^a   Thamilselvan, Sivagnanam ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

catenin; chemotherapy; invasion; metastasis; prostate cancer

Indexed keywords

BETA CATENIN; CYCLIN D1; DEGUELIN; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; SURVIVIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; ROTENONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; EPITHELIUM CELL; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; CELL MOTION; CELL SURVIVAL; DRUG EFFECT; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; ROTENONE; SIGNAL TRANSDUCTION;

EID: 84855161849     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25949     Document Type: Article

References (50)

1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ,. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24. (Pubitemid 19211484)
2. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA,. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827-41. (Pubitemid 15062911)
3. Nelius T, Klatte T, de Riese W, Haynes A, Filleur S,. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 2010; 27: 363-7.
4. Murillo G, Salti GI, Kosmeder JW, 2nd, Pezzuto JM, Mehta RG,. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer 2002; 38: 2446-54. (Pubitemid 35387498)
5. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, Hong WK,. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 2005; 97: 1695-9. (Pubitemid 41672236)
6. Murillo-Godinez G,. [The Flugge's drops]. Rev Med Inst Mex Seguro Soc 2009; 47: 290.
7. Lee JH, Lee DH, Lee HS, Choi JS, Kim KW, Hong SS,. Deguelin inhibits human hepatocellular carcinoma by antiangiogenesis and apoptosis. Oncol Rep 2008; 20: 129-34.
8. Chun KH, Kosmeder JW, 2nd, Sun S, Pezzuto JM, Lotan R, Hong WK, Lee HY,. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003; 95: 291-302. (Pubitemid 36336479)
9. Yi T, Li H, Wang X, Wu Z,. Enhancement radiosensitization of breast cancer cells by deguelin. Cancer Biother Radiopharm 2008; 23: 355-62. (Pubitemid 351931459)
10. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK, Lee HY,. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 2007; 99: 949-61. (Pubitemid 47073501)
11. Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D, Taliferro-Smith L, De Marzo AM,. The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate 2010; 70: 755-64.
12. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS,. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276: 10767-74. (Pubitemid 38089250)
13. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ,. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-7. (Pubitemid 32751073)
14. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505-13.
15. Liao Y, Grobholz R, Abel U, Trojan L, Michel MS, Angel P, Mayer D,. Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer 2003; 107: 676-80. (Pubitemid 37296133)
16. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ,. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005; 10: 975-87.
17. Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, Monia B, Gleave ME, Ong CJ,. Loss of PTEN is associated with progression to androgen independence. Prostate 2006; 66: 895-902. (Pubitemid 43849588)
18. Lawlor MA, Alessi DR,. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903-10. (Pubitemid 32821530)
19. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME,. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41. (Pubitemid 27456390)
20. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC,. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-21. (Pubitemid 28524494)
21. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV,. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21: 893-901. (Pubitemid 32104737)
22. Wang MC, Fu XD, Li MX,. PI-3K/Akt/GSK-3beta signaling cascades stimulated by insulin like growth factor-I contribute to multiple myeloma cells proliferation and survival. Chin Med J (Engl) 2006; 119: 1226-9.
23. Takahashi-Yanaga F, Sasaguri T,. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J Pharmacol Sci 2009; 109: 179-83.
24. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB,. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45: 323-34.
25. Anna CH, Iida M, Sills RC, Devereux TR,. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice. Toxicol Appl Pharmacol 2003; 190: 135-45. (Pubitemid 36870881)
26. Tetsu O, McCormick F,. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6. (Pubitemid 29180374)
27. Raju J, Patlolla JM, Swamy MV, Rao CV,. Diosgenin, a steroid saponin of Trigonella foenum graecum (Fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol Biomarkers Prev 2004; 13: 1392-8. (Pubitemid 39071566)
28. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA,. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9. (Pubitemid 26004411)
29. Song G, Ouyang G, Bao S,. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
30. Datta SR, Brunet A, Greenberg ME,. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-27.
31. Murillo G, Peng X, Torres KE, Mehta RG,. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila) 2009; 2: 942-50.
32. Frame S, Cohen P,. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16. (Pubitemid 32939202)
33. Kren L, Hermanova M, Goncharuk VN, Kaur P, Ross JS, Pavlovsky Z, Dvorak K,. Downregulation of plasma membrane expression/cytoplasmic accumulation of beta-catenin predicts shortened survival in non-small cell lung cancer. A clinicopathologic study of 100 cases. Cesk Patol 2003; 39: 17-20.
34. Ogasawara N, Tsukamoto T, Mizoshita T, Inada K, Cao X, Takenaka Y, Joh T, Tatematsu M,. Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer. Histopathology 2006; 49: 612-21. (Pubitemid 44924293)
35. de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, Buttyan R, Chopin D,. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003; 9: 1801-7. (Pubitemid 36554607)
36. Saleem M, Murtaza I, Tarapore RS, Suh Y, Adhami VM, Johnson JJ, Siddiqui IA, Khan N, Asim M, Hafeez BB, Shekhani MT, Li B, et al. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis 2009; 30: 808-17.
37. Logan CY, Nusse R,. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810. (Pubitemid 39488658)
38. Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, Hoang BH,. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 2005; 65: 9762-70. (Pubitemid 41541453)
39. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J,. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999; 20: 22-45. (Pubitemid 29091458)
40. Ambrosini G, Adida C, Altieri DC,. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21. (Pubitemid 27353455)
41. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H,. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004; 171: 1855-60. (Pubitemid 38501022)
42. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R,. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100: 751-7. (Pubitemid 38176853)
43. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM, Chan AO, Yuen MF, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003; 63: 7724-32. (Pubitemid 37466703)
44. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, Sessa WC,. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000; 275: 9102-5. (Pubitemid 30185122)
45. Kim YH, Lee DH, Jeong JH, Guo ZS, Lee YJ,. Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol 2008; 75: 1946-58.
46. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R,. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-45.
47. Liu QY, Stein CA,. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. Clin Cancer Res 1997; 3: 2039-46. (Pubitemid 27505131)
48. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME,. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005; 4: 1689-98. (Pubitemid 41685303)
49. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC,. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000. (Pubitemid 28078303)
50. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC,. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76. (Pubitemid 26135897)